| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
389,580,000 |
| Market
Cap: |
26.31(B) |
| Last
Volume: |
3,294,635 |
Avg
Vol: |
2,072,018 |
| 52
Week Range: |
$64 - $140.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 520 |
| Guru Rank Value : 3.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
4,915 |
71,783 |
301,616 |
583,537 |
| Total Sell Value |
$371,314 |
$9,377,154 |
$39,059,786 |
$70,857,495 |
| Total People Sold |
5 |
8 |
14 |
16 |
| Total Sell Transactions |
7 |
19 |
46 |
88 |
| End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ace Heather S |
SVP Human Resources |
• – – |
2018-08-23 |
4 |
D |
$141.59 |
$433,412 |
D/D |
(3,061) |
71,171 |
|
- |
|
| Balo Andrew K |
EVP, Reg. Strategy, Clinical |
• – – |
2018-08-14 |
4 |
AS |
$124.16 |
$621,253 |
D/D |
(5,000) |
98,567 |
|
- |
|
| Sayer Kevin R |
President, CEO & Chairman |
• • – |
2018-08-13 |
4 |
AS |
$122.41 |
$1,375,211 |
D/D |
(11,161) |
335,171 |
|
- |
|
| Sayer Kevin R |
President, CEO & Chairman |
• • – |
2018-08-13 |
4 |
OE |
$4.58 |
$51,117 |
D/D |
11,161 |
346,332 |
|
- |
|
| Murphy Patrick Michael |
VP, Legal Aff & Chf Compl Ofcr |
• – – |
2018-08-10 |
4 |
AS |
$121.94 |
$1,552,310 |
D/D |
(12,500) |
33,680 |
|
- |
|
| Augustinos Nicholas |
Director |
– • – |
2018-08-06 |
4 |
S |
$121.77 |
$393,301 |
I/I |
(3,230) |
14,362 |
|
- |
|
| Augustinos Nicholas |
Director |
– • – |
2018-08-06 |
4 |
S |
$120.91 |
$1,099,080 |
D/D |
(9,070) |
7,802 |
|
- |
|
| Moy Jeffrey |
SVP, Operations |
• – – |
2018-08-01 |
4 |
AS |
$94.13 |
$548,872 |
I/I |
(5,831) |
5,061 |
|
- |
|
| Pacelli Steven Robert |
EVP, Strategy & Corp. Dev. |
• – – |
2018-07-25 |
4 |
AS |
$101.46 |
$317,335 |
D/D |
(3,114) |
125,571 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2018-07-23 |
4 |
AS |
$102.31 |
$264,513 |
I/I |
(2,581) |
1,067 |
|
- |
|
| Balo Andrew K |
EVP, Reg. Strategy, Clinical |
• – – |
2018-07-16 |
4 |
AS |
$99.12 |
$497,816 |
D/D |
(5,000) |
103,567 |
|
- |
|
| Gregg Terrance H |
Executive Chairman |
• • – |
2018-07-16 |
4 |
AS |
$99.23 |
$995,561 |
I/I |
(10,000) |
50,882 |
|
- |
|
| Sayer Kevin R |
President & CEO |
• • – |
2018-07-09 |
4 |
AS |
$99.10 |
$1,418,856 |
D/D |
(14,219) |
335,171 |
|
- |
|
| Moy Jeffrey |
SVP, Operations |
• – – |
2018-06-28 |
4 |
AS |
$91.49 |
$5,474,297 |
I/I |
(59,193) |
10,892 |
|
- |
|
| Doubleday Richard |
EVP, Chief Commercial Officer |
• – – |
2018-06-25 |
4 |
AS |
$98.58 |
$254,431 |
I/I |
(2,581) |
3,648 |
|
- |
|
| Gregg Terrance H |
Executive Chairman |
• • – |
2018-06-15 |
4 |
AS |
$97.81 |
$978,096 |
I/I |
(10,000) |
882 |
|
- |
|
| Topol Eric |
Director |
– • – |
2018-06-12 |
4 |
S |
$100.10 |
$2,001,998 |
I/I |
(20,000) |
84,562 |
|
- |
|
| Moy Jeffrey |
SVP, Operations |
• – – |
2018-06-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
315 |
70,085 |
|
- |
|
| Kahn Barbara |
Director |
– • – |
2018-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
4,353 |
27,448 |
|
- |
|
| Kahn Barbara |
Director |
– • – |
2018-06-01 |
4 |
AS |
$0.00 |
$0 |
D/D |
(4,353) |
3,449 |
|
- |
|
| Altman Steven R |
Director |
– • – |
2018-06-01 |
4/A |
A |
$0.00 |
$3 |
D/D |
3,449 |
3,449 |
|
- |
|
| Collins Richard Alexander |
Director |
– • – |
2018-06-01 |
4/A |
A |
$0.00 |
$3 |
D/D |
3,449 |
9,304 |
|
- |
|
| Foletta Mark G |
Director |
– • – |
2018-06-01 |
4/A |
A |
$0.00 |
$4 |
D/D |
4,052 |
4,052 |
|
- |
|
| Skyler Jay S |
Director |
– • – |
2018-06-01 |
4/A |
A |
$0.00 |
$4 |
D/D |
3,607 |
3,607 |
|
- |
|
| Augustinos Nicholas |
Director |
– • – |
2018-06-01 |
4/A |
A |
$0.00 |
$3 |
D/D |
3,449 |
34,464 |
|
- |
|
2316 Records found
|
|
Page 31 of 93 |
|
|
0.80 (1.2%) 
